RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for...
Source: prnewswire.com